These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 15608053

  • 1. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
    Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G, Fisher M, Gazzard B.
    J Antimicrob Chemother; 2005 Feb; 55(2):246-51. PubMed ID: 15608053
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE, COL30336 Study Team.
    HIV Clin Trials; 2003 Feb; 4(4):231-43. PubMed ID: 12916008
    [Abstract] [Full Text] [Related]

  • 4. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR, CNA30024 Study Team.
    Clin Infect Dis; 2004 Oct 01; 39(7):1038-46. PubMed ID: 15472858
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E, GESIDA 3903 Team.
    Clin Infect Dis; 2008 Oct 15; 47(8):1083-92. PubMed ID: 18781872
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
    Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, Casado JL, Dronda F, Gutiérrez C, Quereda C, Navas E, Abraira V, Rodríguez MA.
    HIV Clin Trials; 2005 Oct 15; 6(6):312-9. PubMed ID: 16452065
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
    Ferrer E, Gatell JM, Sanchez P, Domingo P, Puig T, Niubo J, Cortes C, Veloso S, Pedrol E, Leon A, Gutierrez M, Podzamczer D.
    AIDS Res Hum Retroviruses; 2008 Jul 15; 24(7):931-4. PubMed ID: 18671476
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G.
    J Infect Dis; 2008 Oct 15; 198(8):1113-22. PubMed ID: 18783318
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    Girard PM, Cabié A, Michelet C, Verdon R, Katlama C, Mercié P, Morand-Joubert L, Pétour P, Monchecourt F, Chêne G, Trylesinski A, COOL Study Team.
    J Antimicrob Chemother; 2009 Jul 15; 64(1):126-34. PubMed ID: 19403652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.